Health Canada approves AbbVie’s EPKINLY combo for relapsed or refractory follicular lymphoma in adults
Health Canada cleared AbbVie’s EPKINLY (epcoritamab) with lenalidomide, rituximab for relapsed or refractory follicular lymphoma in adults. Use targets grade 1-3A disease in patients with at least one prior systemic therapy. Phase III EPCORE FL-1 showed a 79% lower risk of progression or death versus lenalidomide-ritux